Evidence map›Paper›PMID 42903148›Full record

ArticleFrontiers in immunology2026

Case Report: Immune-related colitis complicated by

Wenjuan Chen, Wanqian Zhang, Chaoqun Sun, Lin Meng, Xiujuan Qu, Ying Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjuan Chen *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Wanqian Zhang *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Chaoqun SunDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Lin MengDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ying ChenDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced microsatellite instability-high (MSI-H) gastric cancer. However, the incidence of immune-related adverse events (irAEs) has also increased accordingly. Immune-related colitis (IRC) is among the most common gastrointestinal manifestations of these irAEs. Case presentation: This report describes a patient with advanced MSI-H gastric cancer who received immunotherapy and developed Grade-3 IRC during treatment. The patient recovered following corticosteroid therapy. Diarrhea recurred after discontinuation of corticosteroids, a condition that may be misdiagnosed as a recurrence of IRC. Following a multidisciplinary team consultation, the patient was clinically diagnosed with Clostridioides difficile infection (CDI) based on symptoms and stool testing, and showed rapid improvement after vancomycin therapy. The patient achieved a durable complete clinical response lasting more than 5 years without further systemic anticancer therapy. Conclusion: This case illustrates that immunotherapy may confer long-term benefit in MSI-H advanced gastric cancer. Notably, the occurrence of immune-related adverse events coincided with sustained tumor control, suggesting a potential association that merits further exploration. However, when diarrhea recurs after discontinuation of corticosteroids, clinicians must remain highly vigilant regarding the overlap and differentiation between the reactivation of IRC and infectious colitis, the involvement of a multidisciplinary team is particularly crucial.

Indexed as

Clostridioides difficileClostridium InfectionsColitisImmune Checkpoint InhibitorsStomach NeoplasmsHumansImmunotherapyMaleTreatment OutcomeImmune Checkpoint Inhibitorscase reportClostridioides difficileimmune-related adverse eventsimmune-related colitismicrosatellite instability-high gastric cancer

Identifiers

PMID42903148
PMCPMC13680402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.